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ABSTRACT
Objectives: To describe and analyse the manifestation of
sclerosing skin disorders in patients with multiple
sclerosis (MS).
Case reports: We describe three patients with relapsing-
remitting MS who developed skin sclerosis while
receiving interferon (IFN)-b treatment and review nine
further cases of systemic sclerosis (SSc) in MS from the
literature. Of all 12 patients reported, eight had limited
cutaneous SSc, three had diffuse cutaneous SSc and one
patient had an antisynthetase syndrome. Localised
scleroderma such as morphoea was not described. The
mean age at diagnosis was 25.2 years for MS (range 12
to 51) and 38.3 years for SSc (range 16 to 66). Eleven
patients developed SSc after the onset of MS and
manifested with skin sclerosis after a mean of 14.9 years
(range 1 to 45). In five patients IFN-b was commenced
before the development of skin sclerosis (mean 4.6 years,
range 1 to 8 years). There was no relationship between
the onset of skin sclerosis and MS activity. With the
exception of one individual, all patients had antinuclear
antibodies.
Conclusions: Sclerosing skin disorders may develop in
the course of MS. The relatively early age of SSc onset in
patients with MS suggests a genetic predisposition and/
or an IFN-associated trigger.
Multiple sclerosis (MS) is a demyelinating disease
mediated by autoreactive T cells. Although a report
suggested an increased prevalence of Sjo¨gren’s
syndrome, an association between MS and con-
nective tissue diseases (CTD) has not been
confirmed in a large cohort.1
Interferon (IFN)-b is frequently used in the
treatment of relapsing-remitting MS. IFN-b may
stimulate autoantibody production, induce auto-
immune disorders in the thyroid and other organs,
and precipitate Raynaud’s phenomenon.2
A parallel occurrence of MS and systemic
sclerosis (SSc) has only been described in a few
individuals. Here, we describe three patients who
were referred to our tertiary care hospital suffering
from MS and having developed a sclerosing skin
disorder while receiving IFN-b treatment. We
review the evidence for a link between both
autoimmune conditions, and the triggering of skin
sclerosis by IFN.
CASE REPORTS
Patient 1
A 54-year-old female patient had developed relap-
sing-remitting MS at the age of 12 years. Since
47 years of age, she had received corticosteroids
and IFN-b, under which her MS remained stable.
At the age of 53 years under continued IFN-b
treatment she noticed Raynaud’s phenomenon
with oedema, sclerodactily and hyperpigmentation
of the nail beds. Digital ulcers, telangiectasias or
synovitis were not present. She had dilated and
distorted nail fold capillaries. There were no
symptoms of gastro-oesophageal reflux.
Echocardiography, lung function tests and a high
resolution computed tomography of the chest were
normal, but anticentromere autoantibodies were
positive (titre 1:5210). Treatment with IFN-b was
not discontinued. The skin status remained stable
and follow-up echocardiography and lung function
test were normal after 2 years.
Patient 2
A 66-year-old woman had developed relapsing-
remitting MS at 21 years of age. IFN-b treatment
was commenced at 58 years of age and had led to a
complete stabilisation of the disease. Eight years
after the initiation of IFN-b, she noted Raynaud’s
phenomenon, arthralgia, myalgia and sclerodactily.
She had not developed digital ulcers, telangiecta-
sias, dysphagia or sicca symptoms. A nail-fold
capillaroscopy and a computerised tomography of
the chest were normal. Her antinuclear antibody
(ANA) titre was 1:80, anti-Jo-1 and anti-SSA
autoantibodies were positive. After 5 months
without cessation of IFN, her skin status remained
stable. At this time, a gastric carcinoma was
diagnosed.
Patient 3
A 59-year-old man was known for relapsing-
remitting MS since the age of 51 years. Since then
he had received IFN-b although this treatment
could not fully prevent recurrent episodes of MS
progression. Since the age of 58, Raynaud’s
phenomenon, sclerodactily and digital ulcers were
observed. He had no dysphagia. Echocardiography,
high resolution computed tomography and lung
function testing did not reveal evidence of cardiac
or pulmonary involvement. His nail-fold capillaro-
scopy was normal but anticentromere autoantibo-
dies were positive (titre 1:1280).
We have described three patients with relapsing-
remitting MS who developed a sclerosing skin
disorder 7–8 years after the initiation of IFN-b
treatment. Two patients were diagnosed with
limited cutaneous scleroderma (lcSSc) and the
third patient had skin sclerosis in association with
antisynthetase autoantibodies.
Extended report
Ann Rheum Dis 2009;68:47–50. doi:10.1136/ard.2007.083246 47
Ta
bl
e
1
S
cl
er
os
in
g
sk
in
di
so
rd
er
s
in
M
S
an
d/
or
ty
pe
1
IF
N
tr
ea
tm
en
t
A
ge
at
on
se
t
of
fi
rs
t
di
se
as
e
(y
ea
rs
)
G
en
de
r
Ti
m
e
of
IF
N
tr
ea
tm
en
t
pr
io
r
to
se
co
nd
di
se
as
e
(y
ea
rs
)
A
ge
at
on
se
t
of
se
co
nd
di
se
as
e
(y
ea
rs
)
C
lin
ic
al
fe
at
ur
es
of
S
S
c
N
ai
l-f
ol
d
ca
pi
lla
ro
sc
op
y
A
N
A
ti
tr
e
A
N
A
sp
ec
if
ic
it
y
S
S
c
in
th
e
co
ur
se
of
M
S
Pa
tie
nt
1
12
Fe
m
al
e
6
(I
FN
-b
)
53
R
P,
sc
le
ro
da
ct
ily
Po
si
tiv
e
1:
52
10
C
en
tr
om
er
e
Pa
tie
nt
2
21
Fe
m
al
e
8
(I
FN
-b
)
66
R
P,
lim
ite
d
sc
le
ro
de
rm
a,
pu
ff
y
ha
nd
s
N
eg
at
iv
e
1:
80
S
S
A
,
Jo
1
Pa
tie
nt
3
51
M
al
e
7
(I
FN
-b
)
58
R
P,
sc
le
ro
da
ct
ily
,
di
gi
ta
l
ul
ce
rs
N
eg
at
iv
e
1:
12
80
C
en
tr
om
er
e
Pe
lid
ou
et
al
20
07
3
26
Fe
m
al
e
1
(I
FN
-b
)
34
R
P,
lim
ite
d
sc
le
ro
de
rm
a,
di
gi
ta
l
ul
ce
rs
,
lu
ng
fib
ro
si
s,
oe
so
ph
ag
ea
l
dy
sm
ot
ili
ty
,
st
ab
ili
sa
tio
n
af
te
r
IF
N
ce
ss
at
io
n
N
D
1:
51
20
–
S
pa
da
ro
et
al
19
99
2
0
26
Fe
m
al
e
1
(I
FN
-b
)
27
R
P,
di
ff
us
e
sc
le
ro
de
rm
a,
di
gi
ta
l
ul
ce
rs
Po
si
tiv
e
Po
si
tiv
e
S
cl
70
,
U
1R
N
P
Ig
ar
as
hi
et
al
19
89
1
6
27
Fe
m
al
e
N
o
IF
N
39
R
P,
di
ff
us
e
sc
le
ro
de
rm
a,
lu
ng
fib
ro
si
s,
oe
so
ph
ag
ea
l
dy
sm
ot
ili
ty
N
D
Po
si
tiv
e
S
cl
70
G
or
od
ki
n
et
al
20
04
1
7
37
Fe
m
al
e
N
o
IF
N
47
R
P,
lim
ite
d
sc
le
ro
de
rm
a,
di
gi
ta
l
ul
ce
rs
,
ca
lc
in
os
is
,
oe
so
ph
ag
ea
l
dy
sm
ot
ili
ty
Po
si
tiv
e
N
eg
at
iv
e
–
G
or
od
ki
n
et
al
20
04
1
7
28
Fe
m
al
e
N
o
IF
N
N
D
R
P,
sc
le
ro
da
ct
ily
,
oe
so
ph
ag
ea
l
dy
sm
ot
ili
ty
Po
si
tiv
e
N
D
C
en
tr
om
er
e
Ja
w
ad
et
al
19
97
1
8
22
Fe
m
al
e
N
o
IF
N
43
R
P,
lim
ite
d
sc
le
ro
de
rm
a,
oe
so
ph
ag
ea
l
dy
sm
ot
ili
ty
N
D
1:
32
0
–
Tr
os
tle
et
al
19
86
1
9
15
Fe
m
al
e
N
o
IF
N
16
R
P,
lim
ite
d
sc
le
ro
de
rm
a
di
gi
ta
l
pi
tt
in
g
sc
ar
s,
te
la
ng
ie
ct
as
ia
s,
ca
lc
in
os
is
,
lu
ng
fib
ro
si
s
N
D
1:
12
8
–
Tr
os
tle
et
al
19
86
1
9
16
Fe
m
al
e
N
o
IF
N
19
R
P,
di
ff
us
e
sc
le
ro
de
rm
a
N
D
1:
40
–
M
S
in
th
e
co
ur
se
of
S
S
c
C
hr
on
i
et
al
20
02
2
1
20
Fe
m
al
e
N
o
IF
N
22
Li
m
ite
d
sc
le
ro
de
rm
a
(f
ac
e
an
d
ha
nd
s)
N
D
1:
64
0
S
cl
70
S
S
c
in
th
e
co
ur
se
of
IF
N
tr
ea
tm
en
t
fo
r
ch
ro
ni
c
H
C
V
in
fe
ct
io
n
Ta
ha
ra
et
al
20
07
2
2
50
Fe
m
al
e
1.
5
(I
FN
-a
)
68
R
P,
lim
ite
d
sc
le
ro
de
rm
a
(f
in
ge
rs
,
fo
re
ar
m
s)
N
eg
at
iv
e
1:
12
80
–
S
ol
an
s
et
al
20
04
1
5
47
Fe
m
al
e
0.
5
(I
FN
-a
)
47
R
P,
sc
le
ro
da
ct
ily
,
te
la
ng
ie
ct
as
ia
s,
ca
lc
in
os
is
,
lu
ng
fib
ro
si
s,
im
pr
ov
em
en
t
af
te
r
IF
N
di
sc
on
tin
ua
tio
n
Po
si
tiv
e
1:
12
80
PM
-S
cl
S
S
C
in
th
e
co
ur
se
of
IF
N
tr
ea
tm
en
t
fo
r
ch
ro
ni
c
m
ye
lo
ge
no
us
le
uk
ae
m
ia
B
er
et
ta
et
al
20
04
2
3
52
Fe
m
al
e
1.
7
(I
FN
-a
)
54
Li
m
ite
d
sc
le
ro
de
rm
a
(f
in
ge
rs
,
w
ris
ts
),
lu
ng
fib
ro
si
s,
al
ve
ol
iti
s,
PA
H
,
oe
so
ph
ag
ea
l
dy
sm
ot
ili
ty
Po
si
tiv
e
Po
si
tiv
e
S
cl
70
A
N
A
,
an
tin
uc
le
ar
an
tib
od
y;
H
C
V
,
he
pa
tit
is
C
vi
ru
s;
IF
N
,
in
te
rf
er
on
;
M
S
,
m
ul
tip
le
sc
le
ro
si
s;
N
D
,
no
t
do
ne
/n
ot
de
sc
rib
ed
;
PA
H
,
pu
lm
on
ar
y
ar
te
ria
l
hy
pe
rt
en
si
on
;
R
P,
R
ay
na
ud
’s
ph
en
om
en
on
;
S
S
c,
sy
st
em
ic
sc
le
ro
si
s.
Th
e
th
re
e
pa
tie
nt
s
in
ou
r
ca
se
se
rie
s
an
d
al
l
ni
ne
fo
un
d
in
lit
er
at
ur
e
ar
e
lis
te
d.
Pa
tie
nt
s
w
ho
de
ve
lo
pe
d
sk
in
sc
le
ro
si
s
af
te
r
re
ce
iv
in
g
IF
N
-a
tr
ea
tm
en
t
fo
r
H
C
V
in
fe
ct
io
n
an
d
m
ye
lo
pr
ol
ife
ra
tiv
e
di
se
as
e
ar
e
al
so
lis
te
d.
Extended report
48 Ann Rheum Dis 2009;68:47–50. doi:10.1136/ard.2007.083246
In the literature, we found nine further cases of MS in
association with SSc (table 1). Six cases had lcSSc, and three had
diffuse cutaneous SSc (dcSSc). Localised scleroderma such as
morphoea or ‘‘en coup de sabre’’ has not been described. Eight
individual had MS prior to the onset of SSc; in only one
individual MS developed after the onset of SSc. One patient,
who had had Raynaud’s phenomenon for 11 years, developed
SSc 1 year after receiving IFN for MS. All but one patient had
elevated ANA titres. The onset of skin sclerosis was dissociated
from MS activity in most of the patients.
In all 12 patients, the mean age of MS diagnosis was
25.2 years (range 12–51). The mean age at the onset of skin
sclerosis was 38.3 years (range 16–66). Skin sclerosis was
therefore preceded by the MS by a mean of 14.9 years (range
1–45).
Five of the 11 patients who developed skin sclerosis after the
onset of MS had received IFN-b. After the initiation of IFN
treatment, skin sclerosis developed after a mean of 4.6 years
(range 1–8). Interestingly, lung fibrosis did not progress and
Raynaud’s phenomenon improved after cessation of IFN
treatment in one MS patient.3
The literature also reports three patients who developed skin
sclerosis while receiving IFN-a, another type 1 IFN (table 1).
Patients had either simultaneous chronic hepatitis C virus
infection or myeloproliferative disease and had developed skin
sclerosis after a mean of 1.2 years (range 0.5–1.7) of IFN-a
treatment. All patients were female and all had high-titre ANAs.
Two patients had SSc, one patient had a PM-Scl positive
collagenosis.
DISCUSSION
The cluster of the three cases described here and a further nine
patients found in the literature prompted us to investigate a
possible relation between MS and SSc. The presence of these
two autoimmune diseases in the same individual raises the
question whether or not this association reflects pure coin-
cidence, an underlying predisposition to develop both auto-
immune diseases, or the stimulation of skin sclerosis by IFN. A
gadolinium triggered dermopathy could be ruled out based on a
normal renal function and the presence of Raynaud’s phenom-
enon in these patients.
Although there is no clear proof of other autoimmune
complications in patients with MS themselves, an increased risk
for autoimmune disease was demonstrated in first-degree relatives
of patients with MS.4 Conversely, approximately one-third of SSc
patients were found to have at least one additional autoimmune
disease.5 The observation that the onset of skin sclerosis in
patients with MS was 9 years before the mean age reported in the
large European Scleroderma Trial and Research cohort (EUSTAR)6
may also be interpreted as an underlying genetic predisposition.
To this end, it is noteworthy that an otherwise rare allele in the
CD45 gene has been found in relatively high frequency in both,
patients with MS and SSc.7 This CD45 allele may enhance T cell
receptor signalling and may thus represent a genetic risk factor for
both autoimmune diseases.7
Elevated ANA titres are found in up to 45% of patients with
MS. Although ANA titres usually remain low in patients with
MS, they are known to be increased by IFN-b exposure.8 Large
observational studies have described the induction of new
autoantibodies in up to 61%, and autoimmune complications in
4–19% of IFN-treated individuals.2 The dynamics of de novo
autoantibody induction in patients with MS by IFN appears to
be delayed, however, as ANA were usually not observed during
the first 6 months of IFN treatment. In most of the patients
with MS summarised here, it is unknown if ANA were present
before IFN was commenced. It is, however, well known that
autoimmune thyroiditis, a frequent complication of IFN
treatment, develops preferentially in subjects harbouring pre-
existing antithyroid autoantibodies.2
Among the CTDs, de novo manifestations of systemic lupus
erythematosus have been observed under IFN-a and IFN-b
treatment,9 the duration of IFN exposure ranging from 1 month
to 7 years. Conversely, systemic lupus erythematosus was
observed to resolve in some cases in which IFN-b was
discontinued.10
A placebo-controlled randomised study has examined IFN-a
as a possible treatment for SSc.11 In this trial, IFN actually
worsened some SSc manifestations and even increased SSc
mortality,11 supporting the possibility that IFN contributes to
skin sclerosis.
In MS, autoreactive T cells are thought to play an important
pathogenic role. In SSc, activated fibroblasts and endothelial cells
have mainly been implicated in the vascular damage and fibrosis,
but an antigen-driven T helper 2 (Th2) cell activation with
consequent enhancement of interleukin 4 expression was also
identified in the aetiology of active SSc.12 A similar Th2 cytokine
pattern also characterises patients with MS after the initiation of
IFN-b treatment.13 Because Th2 cytokines were shown to activate
fibroblasts, it is conceivable that the IFN-mediated Th2 shift
contributes to the development of skin sclerosis.14
The possible role of IFN as a trigger of skin sclerosis is further
supported by cases in which fibrotic complications resolved or
stabilised after IFN cessation.15 On the other hand, only five
patients with MS had received IFN before the appearance of
SSc. We thus conclude that IFN may be a possible, albeit not
necessary cofactor for the development of SSc in patients with
MS.
The decision as to whether IFN treatment should be
discontinued in such cases can only be interdisciplinary and
should be individualised on basis of the activity of both diseases,
the available therapeutic options, and the patient’s personal
priorities.
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